In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to review the current understanding of the condition and propose consensus guidelines for surveillance. This summary provides an overview of the clinical and genetic aspects of this aggressive cancer predisposition syndrome. The expert panel concluded that there is enough evidence to recommend offering cancer surveillance to all individuals diagnosed with LFS, either clinically or through molecular testing. Specifically, they advise the implementation of a modified version of the “Toronto protocol,” which incorporates physical exams, blood tests, and imaging.
